{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 450845964
| IUPAC_name = (1S,2S,4R,8S,11R,12S,15S,16S)-15-[(1-methoxycyclopentyl)oxy]-2,16-dimethyl-5-thiapentacyclo[9.7.0.0²,⁸.0⁴,⁶.0¹²,¹⁶]octadecane
| image = Mepitiostane.png
| width = 250px

<!--Clinical data-->
| tradename = Thioderon
| Drugs.com = {{drugs.com|international|mepitiostane}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = Rx-only
| routes_of_administration = [[Oral administration|Oral]]

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion = 

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 21362-69-6
| ATC_prefix = None
| ATC_suffix = 
| ATC_supplemental = 
| PubChem = 9909202
| DrugBank = 
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 8084854
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = O00404969K
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01602

<!--Chemical data-->
| C=25 | H=40 | O=2 | S=1 
| molecular_weight = 404.64 g/mol
| SMILES = C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OC4(CCCC4)OC)CC[C@@H]5[C@@]3(C[C@@H]6[C@H](C5)S6)C
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C25H40O2S/c1-23-13-10-19-17(7-6-16-14-20-21(28-20)15-24(16,19)2)18(23)8-9-22(23)27-25(26-3)11-4-5-12-25/h16-22H,4-15H2,1-3H3/t16-,17-,18-,19-,20-,21+,22-,23-,24-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = IVDYZAAPOLNZKG-KWHRADDSSA-N
| synonyms = 10364-S; Epitiostanol 17β-(1-methoxy)cyclopentyl ether; 17β-[(1-Methoxycyclopentyl)oxy]-2α,3α-epithio-5α-androstane
}}

'''Mepitiostane''' (brand name '''Thioderon''') is an [[oral administration|orally active]] [[steroid]]al [[antiestrogen]] and [[anabolic-androgenic steroid]] (AAS) of the [[dihydrotestosterone]] (DHT) group which is marketed in [[Japan]] as an [[antineoplastic agent]] for the treatment of [[breast cancer]].<ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA768|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=768}}</ref><ref name="IndexNominum2000">{{cite book|title=Index Nominum 2000: International Drug Directory|url=https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA648|date=January 2000|publisher=Taylor & Francis|isbn=978-3-88763-075-1|pages=648–}}</ref><ref name="MortonHall2012">{{cite book|author1=I.K. Morton|author2=Judith M. Hall|title=Concise Dictionary of Pharmacological Agents: Properties and Synonyms|url=https://books.google.com/books?id=tsjrCAAAQBAJ&pg=PA175|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-94-011-4439-1|pages=175–}}</ref><ref name="Erslev1991">{{cite book|author=Allan J. Erslev|title=Erythropoietin: molecular, cellular, and clinical biology|url=https://books.google.com/books?id=CFtsAAAAMAAJ|year=1991|publisher=Johns Hopkins University Press|isbn=978-0-8018-4221-4|page=229}}</ref> It is a [[prodrug]] of [[epitiostanol]].<ref name="StellaBorchardt2007" /><ref name="BorchardtSmith2013">{{cite book|author1=Ronald T. Borchardt|author2=Philip L. Smith|author3=Glynn Wilson|title=Models for Assessing Drug Absorption and Metabolism|url=https://books.google.com/books?id=eS0BCAAAQBAJ&pg=PA101|date=29 June 2013|publisher=Springer Science & Business Media|isbn=978-1-4899-1863-5|pages=101–}}</ref> The drug was patented and described in 1968.<ref name="Elks2014" />

==Medical uses==
Mepitiostane is used as an antiestrogen and antineoplastic agent in the treatment of breast cancer.<ref name="Elks2014" /><ref name="IndexNominum2000" /><ref name="MortonHall2012" /><ref name="Erslev1991" /> It is also used as an AAS in the treatment of [[anemia]] of [[renal failure]].<ref name="Erslev1991" /> A series of [[case report]]s have found it to be effective in the treatment of an [[estrogen receptor]] (ER)-dependent [[meningioma]]s as well.<ref name="Newton2005" /><ref name="Lee2008">{{cite book|author=Joung H. Lee|title=Meningiomas: Diagnosis, Treatment, and Outcome|url=https://books.google.com/books?id=c_j9piinzy8C&pg=PA293|date=11 December 2008|publisher=Springer Science & Business Media|isbn=978-1-84628-784-8|pages=293–5}}</ref><ref name="OuraSakurai2000">{{cite journal|last1=Oura|first1=Shoji|last2=Sakurai|first2=Takeo|last3=Yoshimura|first3=Goro|last4=Tamaki|first4=Takeshi|last5=Umemura|first5=Teiji|last6=Kokawa|first6=Yozo|last7=Masuo|first7=Osamu|last8=Naito|first8=Yasuaki|title=Regression of a presumed meningioma with the antiestrogen agent mepitiostane|journal=Journal of Neurosurgery|volume=93|issue=1|year=2000|pages=132–135|issn=0022-3085|doi=10.3171/jns.2000.93.1.0132}}</ref><ref name="pmid25082321">{{cite journal|vauthors=Miyai M, Takenaka K, Hayashi K, Kato M, Uematsu K, Murai H|title=[Effect of an oral anti-estrogen agent (mepitiostane) on the regression of intracranial meningiomas in the elderly]|language=Japanese|journal=Brain Nerve|volume=66|issue=8|pages=995–1000|year=2014|pmid=25082321|doi=}}</ref> 

==Side effects==
{{See also|Anabolic steroid#Adverse effects}}

Mepitiostane shows a high rate of [[virilizing]] [[side effect]]s such as [[acne]], [[hirsutism]], and [[voice change]]s in women.<ref name="pmid657160">{{cite journal | vauthors = Inoue K, Okazaki K, Morimoto T, Hayashi M, Uyama S, Sonoo H, Koshiba Y, Takihara T, Nomura Y, Yamagata J, Kondo H, Kanda K, Takenaka K | title = Therapeutic value of mepitiostane in the treatment of advanced breast cancer|journal=Cancer Treat Rep|volume=62|issue=5|pages=743–5|year=1978|pmid=657160|doi=}}</ref>

==Pharmacology==
Mepitiostane is described as similar to [[tamoxifen]] as an antiestrogen,<ref name="Newton2005">{{cite book|author=Herbert B. Newton|title=Handbook of Brain Tumor Chemotherapy|url=https://books.google.com/books?id=Igz0_abuL5wC&pg=PA470|date=19 December 2005|publisher=Academic Press|isbn=978-0-08-045593-8|pages=470–}}</ref> and through its active form epitiostanol, binds directly to and [[receptor antagonist|antagonizes]] the ER.<ref name="pmid922732">{{cite journal | vauthors = Matsuzawa A, Yamamoto T | title = Antitumor effect of two oral steroids, mepitiostane and fluoxymesterone, on a pregnancy-dependent mouse mammary tumor (TPDMT-4) | journal = Cancer Res. | volume = 37 | issue = 12 | pages = 4408–15 | year = 1977 | pmid = 922732 | doi = | url = }}</ref><ref name="Timmerman1995">{{cite book|author=H. Timmerman|title=QSAR and Drug Design: New Developments and Applications|url=https://books.google.com/books?id=I-Y4u2OQ5M0C&pg=PA145|date=20 November 1995|publisher=Elsevier|isbn=978-0-08-054500-4|pages=125, 145}}</ref><ref>{{cite book|title=INTERNATIONAL REVIEW OF CYTOLOGY|url=https://books.google.com/books?id=8SuUZFjkGpwC&pg=PA319|date=27 June 1986|publisher=Academic Press|isbn=978-0-08-058640-3|pages=319–}}</ref><ref name="CrollWang2007">{{cite journal|last1=Croll|first1=Roger P.|last2=Wang|first2=Chunde|title=Possible roles of sex steroids in the control of reproduction in bivalve molluscs|journal=Aquaculture|volume=272|issue=1-4|year=2007|pages=76–86|issn=0044-8486|doi=10.1016/j.aquaculture.2007.06.031}}</ref> It is also an AAS.<ref name="Elks2014" /><ref name="MortonHall2012" />

==Chemistry==
{{See also|List of androgens/anabolic steroids}}

Mepitiostane, also known as '''epitiostanol 17β-(1-methoxy)cyclopentyl ether''',<ref name="StellaBorchardt2007">{{cite book|author1=Valentino Stella|author2=Ronald Borchardt|author3=Michael Hageman|author4=Reza Oliyai|author5= Hans Maag|author6= Jefferson Tilley|title=Prodrugs: Challenges and Rewards|url=https://books.google.com/books?id=qkjHxX5TgHEC&pg=PA660|date=12 March 2007|publisher=Springer Science & Business Media|isbn=978-0-387-49782-2|pages=660–}}</ref> is a [[synthetic compound|synthetic]] [[androstane]] [[steroid]] and a [[chemical derivative|derivative]] of DHT.<ref name="Elks2014" /><ref name="IndexNominum2000" /><ref name="MortonHall2012" /> It is the C17β (1-methoxy)cyclopentyl [[ether]] of epitiostanol, which itself is 2α,3α-epithio-DHT or 2α,3α-epithio-5α-androstan-17β-ol.<ref name="StellaBorchardt2007" /><ref name="BorchardtSmith2013">{{cite book|author1=Ronald T. Borchardt|author2=Philip L. Smith|author3=Glynn Wilson|title=Models for Assessing Drug Absorption and Metabolism|url=https://books.google.com/books?id=eS0BCAAAQBAJ&pg=PA101|date=29 June 2013|publisher=Springer Science & Business Media|isbn=978-1-4899-1863-5|pages=101–}}</ref> A related AAS is [[methylepitiostanol]] (17α-methylepitiostanol), which is an orally active variant of epitiostanol similarly to mepitiostane, though also has a risk of [[hepatotoxicity]].<ref name="pmid25684733">{{cite journal|first1=C. D.|last1=Rahnema|first2=L. E.|last2=Crosnoe|first3=E. D.|last3=Kim|title=Designer steroids – over-the-counter supplements and their androgenic component: review of an increasing problem|url=http://onlinelibrary.wiley.com/doi/10.1111/andr.307/abstract|journal=Andrology|date=March 2015|issn=2047-2927|pages=150–155|volume=3|issue=2|doi=10.1111/andr.307|pmid=25684733}}</ref>

==Society and culture==

===Generic name===
''Mepitiostane'' is the {{abbrlink|INN|International Nonproprietary Name}} and {{abbrlink|JAN|Japanese Accepted Name}} of the drug.<ref name="Elks2014" /><ref name="IndexNominum2000" /><ref name="MortonHall2012" />

==References==
{{Reflist|2}}

{{Estrogens and antiestrogens}}
{{Androgens and antiandrogens}}
{{Estrogen receptor modulators}}
{{Androgen receptor modulators}}

[[Category:Alcohols]]
[[Category:Androgens and anabolic steroids]]
[[Category:Androstanes]]
[[Category:Antineoplastic drugs]]
[[Category:Antiestrogens]]
[[Category:Cyclopentanes]]
[[Category:Ethers]]
[[Category:Prodrugs]]
[[Category:Thiiranes]]